Safety And Immunogenicity Of A Recombinant Interferon-Armed Rbd Dimer Vaccine (V-01) For Covid-19 In Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
EMERGING MICROBES & INFECTIONS（2021）
Key words
COVID-19, Phase I, clinical trial, recombinant protein vaccine, RBD dimer, safety, immunogenicity, elderly participants
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined